Answers are grounded in this paper and cite their sources.
Denosumab as part of neoadjuvant therapy, although not improving the pCR rate, significantly reduced the risk of distant relapses. Other long-term outcome parameters did not differ between the treatment arms. TNBC patients, especially when not achieving pCR, seem to benefit from weekly nPac.
No takes yet. Share an insight, caveat, or question.
Link et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: